Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer
作者： Fairooz F. Kabbinavar , Julie Hambleton , Robert D. Mass , Herbert I. Hurwitz , Emily Bergsland
关键词:
摘要: Purpose Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA), a recombinant, humanized anti–vascular endothelial growth factor monoclonal antibody that inhibits tumor angiogenesis, has demonstrated survival benefit in patients with previously untreated metastatic colorectal cancer when combined irinotecan/fluourouracil (FU)/leucovorin (LV; IFL). Three randomized clinical studies have evaluated bevacizumab combination FU/LV alone. A analysis of raw data from these was performed to better assess the efficacy FU/LV. Patients and Methods The used primary three independent studies, including 241 control group receiving either or IFL 249 FU/LV/bevacizumab (5 mg/kg once every 2 weeks). included response rate, progression-free survival, overall survival. Results median duration 17.9 months group, compared ...
jco.org参考文章(25)
G Freyer, P Rougier, R Bugat, J-P Droz, M Marty, H Bleiberg, D Mignard, L Awad, P Herait, S Culine, V Trillet-Lenoir, Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure British Journal of Cancer. ,vol. 83, pp. 431- 437 ,(2000) , 10.1054/BJOC.2000.1303
P Rougier, R Bugat, J Y Douillard, S Culine, E Suc, P Brunet, Y Becouarn, M Ychou, M Marty, J M Extra, J Bonneterre, A Adenis, J F Seitz, G Ganem, M Namer, T Conroy, S Negrier, Y Merrouche, F Burki, M Mousseau, P Herait, M Mahjoubi, Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. Journal of Clinical Oncology. ,vol. 15, pp. 251- 260 ,(1997) , 10.1200/JCO.1997.15.1.251
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. Journal of Clinical Oncology. ,vol. 22, pp. 3766- 3775 ,(2004) , 10.1200/JCO.2004.03.104
K Jin Kim, Bing Li, Jane Winer, Mark Armanini, Nancy Gillett, Heidi S Phillips, Napoleone Ferrara, None, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature. ,vol. 362, pp. 841- 844 ,(1993) , 10.1038/362841A0
J.A. Langendijk, Ch.R. Leemans, J. Buter, J. Berkhof, B.J. Slotman, The Additional Value of Chemotherapy to Radiotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Meta-Analysis of the Published Literature Journal of Clinical Oncology. ,vol. 22, pp. 4604- 4612 ,(2004) , 10.1200/JCO.2004.10.074
Mace L. Rothenberg, John V. Cox, Russell F. DeVore, John D. Hainsworth, Richard Pazdur, Saul E. Rivkin, John S. Macdonald, Charles E. Geyer, John Sandbach, Daniel L. Wolf, J. Scott Mohrland, Gary L. Elfring, Langdon L. Miller, Daniel D. Von Hoff, A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. ,vol. 85, pp. 786- 795 ,(1999) , 10.1002/(SICI)1097-0142(19990215)85:4<786::AID-CNCR5>3.0.CO;2-9
Napoleone Ferrara, Terri Davis-Smyth, THE BIOLOGY OF VASCULAR ENDOTHELIAL GROWTH FACTOR Endocrine Reviews. ,vol. 18, pp. 4- 25 ,(1997) , 10.1210/EDRV.18.1.0287
Fairooz Kabbinavar, Herbert I. Hurwitz, Louis Fehrenbacher, Neal J. Meropol, William F. Novotny, Grazyna Lieberman, Susan Griffing, Emily Bergsland, Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 21, pp. 60- 65 ,(2003) , 10.1200/JCO.2003.10.066
H. Bleiberg, E. Cvitkovic, Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. European Journal of Cancer. ,vol. 32, ,(1996) , 10.1016/0959-8049(96)00293-6
Martin M. Oken, Richard H. Creech, Douglass C. Tormey, John Horton, Thomas E. Davis, Eleanor T. McFadden, Paul P. Carbone, Toxicity and response criteria of the Eastern Cooperative Oncology Group American Journal of Clinical Oncology. ,vol. 5, pp. 649- 655 ,(1982) , 10.1097/00000421-198212000-00014